Literature DB >> 1002102

Somatomedin production in the neonatal rat.

M C Stuart, L Lazarus, S S Moore, G A Smythe.   

Abstract

The hormonal stimulus to rat fetal and neonatal somatic and skeletal growth has been investigated by a study of ciruclating somatomedin (SM), growth hormone (GH) and insulin levels in rats from 21 days in utero to 40 days of post natal life. Somatomedin activity could not be detected in the serum of fetal rats in which circulating GH and insulin levels were high. In early post natal life GH and insulin levels remained high but gradually declined reaching normal adult levels at 19 days and 40 days respectively. Somatomedin activity was measurable only at low levels until 11 days after birth and thereafter remained steady throughout the time period studied. These studies suggest that somatomedin alone is not responsible for the rapid growth of the rat in early neonatal life and it is suggested that insulin may also be active as a growth factor in this period.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1002102     DOI: 10.1055/s-0028-1093610

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  4 in total

1.  Human fetal cartilage response to plasma somatomedin activity in relation to gestational age.

Authors:  I K Ashton; S Phizackerley
Journal:  Calcif Tissue Int       Date:  1981       Impact factor: 4.333

2.  Increased levels of multiplication-stimulating activity, an insulin-like growth factor, in fetal rat serum.

Authors:  A C Moses; S P Nissley; P A Short; M M Rechler; R M White; A B Knight; O Z Higa
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

3.  Growth of the nasal septal cartilage of the rat in vitro.

Authors:  J C Copray
Journal:  J Anat       Date:  1986-02       Impact factor: 2.610

4.  Developmental pattern of a serum binding protein for multiplication stimulating activity in the rat.

Authors:  R M White; S P Nissley; P A Short; M M Rechler; I Fennoy
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.